Matthew Wiley - Jun 15, 2024 Form 4/A - Amendment Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Commercial Officer
Signature
/s/ Richard Steinhart, as Attorney-in-Fact for Matthew T. Wiley
Stock symbol
BTAI
Transactions as of
Jun 15, 2024
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/17/2024, 07:17 PM
Date Of Original Report
Jun 18, 2024
Previous filing
Apr 8, 2024
Next filing
Sep 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -750 -8.33% $0.00 8.25K Jun 15, 2024 Common Stock 750 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 On March 15, 2023, the Reporting Person was granted 12,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Remarks:

This Form 4/A is being filed to disclose the disposition of 750 RSUs. Column 5 of Table II in the Form 4 filed on June 18, 2024 inadvertently and improperly showed that these securities were acquired. Column 9 of Table II remains unchanged from the June 18, 2024 filing.